-+ 0.00%
-+ 0.00%
-+ 0.00%

Sangamo Therapeutics Announces Topline Results From Registrational Phase 1/2 STAAR Of ST-920 In Fabry Disease; Intends To Submit Biologics License Application In 2026

Benzinga·06/24/2025 12:10:25
Listen to the news

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval

Isaralgagene civaparvovec showed a favorable safety and tolerability profile